Ainos, Inc. (AIMD)
$
3.82
-0.16 (-4.19%)
Key metrics
Financial statements
Free cash flow per share
-1.2012
Market cap
17.8 Million
Price to sales ratio
160.2453
Debt to equity
0.9613
Current ratio
2.8766
Income quality
0.3125
Average inventory
150.9 Thousand
ROE
-1.0825
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ainos, Inc. is a healthcare company that specializes in the development of medical technologies aimed at point-of-care testing and innovative treatments for various disease indications. The company has made significant strides in its financial performance, as evidenced by its operating income ratio of -667.72 indicating the company's operational profitability margin. Additionally, the gross profit ratio stands at -1.54 reflecting the efficiency of the company's production and sales operations. Ainos achieved a revenue of $20,729.00 showcasing its focus on niche markets. However, the company also incurred an interest expense of $616,467.00 highlighting its obligations related to debt servicing. The weighted average number of shares outstanding is 9,503,618.00 which underscores the company's shareholder base and their stake in the firm. Ainos offers a range of products, including a COVID-19 antigen rapid test kit, a cloud-based test management platform, and a low-dose oral interferon alpha formulation known as Very Low-Dose Oral Interferon Alpha, among other technologies. Formerly known as Amarillo Biosciences, Inc., the company rebranded to Ainos, Inc. in May 2021 and has its headquarters in San Diego, California. The company's stock presents an attractive option for budget-conscious investors, as it is affordable at $2.88. However, it's important to note that the stock has a low average trading volume of 2,330,460.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $17,766,396.00 Ainos is classified as a small-cap player within the healthcare market. It operates within the Biotechnology industry and plays a crucial role in enhancing the overall market landscape. Furthermore, Ainos belongs to the Healthcare sector, where it continues to drive innovation and growth through its advanced medical technologies. The company's strategic focus on point-of-care testing and treatment positions it effectively in the evolving healthcare landscape, allowing it to contribute meaningfully to patient care and medical advancements.
Is Ainos, Inc. (AIMD) a good investment?
Investing in Ainos, Inc. (AIMD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ainos, Inc. (AIMD)'s stock forecast?
Analysts predict Ainos, Inc. stock to fluctuate between $2 (low) and $5 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ainos, Inc.'s market capitalization?
As of 2025-08-29, Ainos, Inc.'s market cap is $17,766,396, based on 4,650,889 outstanding shares.
How does Ainos, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ainos, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ainos, Inc. (AIMD) stock?
To buy Ainos, Inc. (AIMD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AIMD. Place an order (Market, Limit, etc.).
What is the best time to invest in Ainos, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ainos, Inc. stock ever split?
Ainos, Inc.'s last stock split was 1:5 on 2025-06-30.
How did Ainos, Inc. perform in the last earnings report?
Revenue: $20,729 | EPS: -$1.56 | Growth: -53.57%.
Where can I find Ainos, Inc.'s investor relations reports?
Visit https://ainos.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ainos, Inc.?
You can explore historical data from here
What is the all-time high and low for Ainos, Inc. stock?
All-time high: $90 (2022-08-04) | All-time low: $0.40 (2024-11-15).
What are the key trends affecting Ainos, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
From biotech to SmellTech, Ainos transforms as a first mover in next-gen sensory AI Proprietary smell language model and scent data create unique competitive moat SmellTech flywheel spins toward 2026 scale-up, turning data into recurring revenue SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent detection, today announced that Water Tower Research ("WTR") has published a report spotlighting AI Nose's first-mover breakthrough in giving AI the sense of smell, along with the Company's commercialization roadmap and pathway to profitability. The report draws insights from a management fireside chat on August 20, 2025.
accessnewswire.com
Early revenues and $2.1M SmellTech-as-a-Service order set the stage for large-scale commercialization in 2026 Robotics and industrial deployments expand long-term growth runway beyond healthcare SAN DIEGO, CA / ACCESS Newswire / August 19, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent detection, today announced that Water Tower Research ("WTR") has assumed coverage of Ainos under its Technology research platform, transitioning from its prior coverage under the Emerging Growth category. This move underscores Ainos' strategic transformation from biotech roots to a multi-sector AI technology innovator, with its proprietary AI Nose platform poised to ignite the Company's next phase of growth across healthcare, robotics, and industrial applications.
accessnewswire.com
Patented AI Olfaction Platform Targets Semiconductor, Smart Factory, and Hospital Markets With First Deployments Underway SmellTech-as-a-Service Subscription Delivers AI Upgrades and Analytics, Keeping Enterprises Ahead in Scent Intelligence. Debuting at Automation Taipei 2025 in Partnership with Kenmec and ugo SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 14, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent detection, today launched its first commercial AI Nose module optimized for industrial and healthcare settings, marking a pivotal milestone in the global commercialization of AI-powered digital olfaction.
accessnewswire.com
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research, on Wednesday, August 20, 2025, at 11:00 a.m. ET. Ainos will highlight the uniqueness of its AI Nose technology, underscoring recent strategic partnerships and the rapid acceleration of AI Nose deployment.
accessnewswire.com
Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with ASE Technology Holding Co., Ltd. ("ASEH", TWSE: 3711, NYSE: ASX), the world's leading provider of semiconductor assembly and test services.
accessnewswire.com
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 26, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it will implement a consolidation of its common stock ("stock consolidation"), effective at the opening of trading on June 30, 2025. This strategic action positions Ainos to attract broader institutional interest as it enters a commercial execution phase in the second half of 2025 and supports the Company's continued Nasdaq listing.
accessnewswire.com
Ainos Hits Inflection Point with AI Nose Pilot Ramp in Senior Care, Robotics, and Semiconductors Key VELDONA® Human Clinical Studies Secure Taiwan Regulatory Greenlight, Accelerating Development SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' critical milestones and strategic advancements in 1H25, and its robust roadmap for the remainder of the year, with multiple large scale AI Nose pilot programs and Veldona ® clinical trials on deck. Key Highlights from the Report: Breakthroughs in accuracy and revenues demonstrate senior care market readiness: AI Nose achieved an 85% accuracy rate in hygiene monitoring, exceeding a performance target of 80%.
accessnewswire.com
Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025.
accessnewswire.com
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") and John Roy, managing director of WTR on Tuesday, April 8, 2025, at 10:00 a.m. ET. Ainos will provide insights into AI Nose applications, including its use in smart manufacturing and robots, as well as the impact of AI-driven digitized smell on industries beyond healthcare.
accessnewswire.com
Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQAIMDW) ("Ainos", or the "Company") today announced its financial results for the fiscal year ended December 31, 2024. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "2024 marked another pivotal year as we transitioned from our COVID-19 antigen rapid test business to advancing the VELDONA® and pioneering AI Nose programs.
See all news
